PepGen Inc. is under investigation by Pomerantz LLP for potential securities fraud following the FDA's partial clinical hold on its Phase 2 trial for a myotonic dystrophy treatment. The FDA's hold was due to concerns about preclinical pharmacology and toxicology data. This announcement caused PepGen's stock to fall 18.57%, closing at $5.50 on March 5, 2026. Investors affected by this are advised to contact Pomerantz LLP for potential class action participation.
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Ipsen Pharma conducted share buybacks from July 6 to July 10, 2026, purchasing a total of 28,541 shares. The average purchase price was €166.05 per share. These buybacks were made under Article 5 of the MAR regulation, indicating a structured repurch...
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
